We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.5%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.94B
AUM Growth
+$354M
Cap. Flow
+$71.5M
Cap. Flow %
2.43%
Top 10 Hldgs %
43.94%
Holding
91
New
27
Increased
20
Reduced
25
Closed
12

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$85.5M
2
QURE icon
uniQure
QURE
+$52M
3
LH icon
Labcorp
LH
+$50.7M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$46.9M
5
IFRX icon
InflaRx
IFRX
+$40.6M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$78.7M
2
PBYI icon
Puma Biotechnology
PBYI
+$74.6M
3
PEN icon
Penumbra
PEN
+$67.6M
4
ABT icon
Abbott
ABT
+$39.2M
5
RGNX icon
Regenxbio
RGNX
+$27.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.2%
2 Miscellaneous 1.77%
3 Financials 1.03%
4 Technology 0%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$268M 9.11%
15,978,580
-1,245,848
-7% -$19.8M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$164M 5.58%
10,511,732
-226,926
-2% -$3.43M
ATRA icon
3
Atara Biotherapeutics
ATRA
$92.3M
$152M 5.15%
165,065
-4,376
-3% -$4.7M
IMGN
4
DELISTED
Immunogen Inc
IMGN
$120M 4.07%
12,315,942
+2,613,460
+27% +$27.6M
XNCR icon
5
Xencor
XNCR
$1.94B
$116M 3.96%
3,147,043
-57,300
-2% -$1.97M
RGNX icon
6
Regenxbio
RGNX
$638M
$112M 3.81%
1,561,175
-569,797
-27% -$27.2M
ALDR
7
DELISTED
Alder Biopharmaceuticals
ALDR
$103M 3.49%
6,505,766
– –
WCG
8
DELISTED
Wellcare Health Plans, Inc.
WCG
$87.4M 2.97%
355,009
+12,700
+4% +$2.77M
WVE icon
9
Wave Life Sciences
WVE
$993M
$85.9M 2.92%
2,244,507
+6,900
+0.3% +$297K
BOLD
10
DELISTED
Audentes Therapeutics, Inc
BOLD
$85.2M 2.89%
2,228,656
+920,130
+70% +$34.1M
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
$80M 2.72%
+1,758,600
New +$85.5M
FATE icon
12
Fate Therapeutics
FATE
$291M
$75.5M 2.56%
6,655,962
– –
IFRX icon
13
InflaRx
IFRX
$329M
$65.4M 2.22%
2,027,700
+1,176,600
+138% +$40.6M
CNC icon
14
Centene
CNC
$32B
$62.6M 2.13%
1,015,970
-103,630
-9% -$5.98M
QURE icon
15
uniQure
QURE
$3.38B
$61.4M 2.09%
+1,624,400
New +$52M
ALXN
16
DELISTED
Alexion Pharmaceuticals
ALXN
$60.7M 2.06%
489,300
+84,500
+21% +$9.88M
LIVN icon
17
LivaNova
LIVN
$4.43B
$59.9M 2.03%
599,788
+81,500
+16% +$7.4M
DCPH
18
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$58.1M 1.97%
1,477,080
+655,800
+80% +$19.3M
ARGX icon
19
argenx
ARGX
$64B
$55.8M 1.9%
673,300
+434,700
+182% +$38.9M
ICUI icon
20
ICU Medical
ICUI
$4.38B
$54.1M 1.84%
184,172
-9,300
-5% -$2.54M
LH icon
21
Labcorp
LH
$27.2B
$51.8M 1.76%
+335,698
New +$50.7M
INSM icon
22
Insmed
INSM
$25.9B
$48.1M 1.63%
2,033,492
-132,870
-6% -$3.42M
SYNH
23
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$46M 1.56%
981,673
-544,431
-36% -$22.5M
XERS icon
24
Xeris Biopharma Holdings
XERS
$1.55B
$45.8M 1.56%
+2,412,642
New +$46.9M
BLUE
25
DELISTED
bluebird bio
BLUE
$42.1M 1.43%
20,728
+108
+0.5% +$246K
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2018 Portfolio in Review

As of Q2 2018, Redmile Group held 91 positions worth $2.94B, up 14% from $2.59B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group's Q2 2018 filing shows 27 new, 20 increased, 25 reduced and 12 closed positions. Its largest new stake was Clovis Oncology, Inc.: 1,758,600 shares worth $80M. The largest sale was AveXis, Inc. Common Stock, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2018 buy was Clovis Oncology, Inc.: 1,758,600 shares worth $80M.
  • Redmile Group added most to InflaRx in Q2 2018, an estimated $40.6M increase.
  • Redmile Group's biggest Q2 2018 reduction was Penumbra, cutting an estimated $67.6M.
  • Redmile Group fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $78.7M.
  • Redmile Group's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2018.
  • Redmile Group opened 27 new positions and closed 12 in Q2 2018.
  • Redmile Group's portfolio value rose 14% quarter-over-quarter to $2.94B.

Based on Redmile Group's 13F filing for Q2 2018, filed 14 Aug 2018.